Blueprint Medicines Corp (BPMC) USD0.001
1.26%- This stock can be held in a
Stocks and Shares ISA
$1.57
(1.82%)$1.57
(1.82%)Company Information
About this company
Blueprint Medicines Corporation is a fully integrated, commercial-stage, global biopharmaceutical company. The Company invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. It has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. It is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. It is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
Key people
Key facts
- EPICBPMC
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS09627Y1091
- Market cap$5.48bn
- Employees649
- Shares in issue64.58m
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.